July 24, 2019 | City of Hope
An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.
Bringing Leading-edge Care to the Community: Hans Schoellhammer, M.D.
June 13, 2018 | Travis Marshall
Surgical oncologist Hans Schoellhammer, M.D., has always been fascinated by the immunotherapies that help a patient’s own immune system attack cancer, and at City of Hope, he focuses his talents on treating melanoma.
Looking Ahead: A Conversation with Steven T. Rosen, M.D., Provost and Chief Scientific Officer
May 30, 2018 | Michael Easterling
Steven T. Rosen, M.D., just marked his fourth year at City of Hope as provost and chief scientific officer. On the occasion of his first four years at City of Hope and the recent five-year renewal of a National Cancer Institute grant, we sat down with Rosen to reflect on his time at City of Hope.
CTCL Patient Offers High Praise for City of Hope Derm Team
May 22, 2018 | Robert Young
When what he thought was just a rash on his forehead spread to his face and neck, Joshua Singer sought medical help. After a number of treatments failed to figure out the problem, he turned to City of Hope, and renowned dermatologist Christiane Querfeld. M.D., Ph.D.
Chemo-Toxicity Calculator identifies risks in older adults with cancer
December 4, 2017 | City of Hope
City of Hope’s Arti Hurria, M.D., and colleagues developed a chemotherapy toxicity calculator to identify the risk for chemotherapy toxicity in older adults with cancer.
Geriatric assessment guides treatment strategy for older adults with cancer
December 1, 2017 | City of Hope
Researchers developed a self-administered geriatric assessment to identify areas of vulnerability and guide interventions for older adults with cancer.
Cancer Insights: Molecular profiling unlocks tumor answers
October 27, 2016 | Sumanta K. Pal, M.D.
Molecular profiling, unlike any other type of controversial profiling in the news, is an extremely hot topic in cancer medicine today, and it’s going to have a huge impact on patients, physicians and payers.